Baldwin Brothers LLC Vertex Pharmaceuticals Inc Transaction History

Baldwin Brothers LLC

$13.5 Billion
Q4 2024

A detailed history of Baldwin Brothers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baldwin Brothers LLC holds 8,997 shares of VRTX stock, worth $4.24 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

8,997

Previous 8,997 -0.0%

Holding current value

$4.24 Million

Previous $4.18 Million 13.41%

% of portfolio

0.03%

Previous 0.29%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$460.0 - $505.78 $5,060 - $5,563	11 Added 0.12%	8,997 $4.18 Million
Q2 2024 Jul 12, 2024	BUY	$392.81 - $485.53 $1,571 - $1,942	4 Added 0.04%	8,986 $4.21 Million
Q1 2024 Apr 12, 2024	SELL	$407.69 - $446.08 $77,461 - $84,755	-190 Reduced 2.07%	8,982 $3.75 Million
Q4 2023 Jan 08, 2024	BUY	$343.0 - $410.68 $12,005 - $14,373	35 Added 0.38%	9,172 $3.73 Million
Q3 2023 Oct 10, 2023	SELL	$338.18 - $362.46 $84,545 - $90,615	-250 Reduced 2.66%	9,137 $3.18 Million
Q4 2022 Jan 27, 2023	BUY	$285.76 - $321.48 $2.66 Million - $2.99 Million	9,312 Added 12416.0%	9,387 $0
Q4 2019 Jan 29, 2020	SELL	$166.71 - $223.91 $666 - $895	-4 Reduced 5.06%	75 $16,000
Q3 2019 Oct 10, 2019	SELL	$166.23 - $187.09 $152,599 - $171,748	-918 Reduced 92.08%	79 $14,000
Q2 2019 Jul 19, 2019	SELL	$164.61 - $190.37 $37,201 - $43,023	-226 Reduced 18.48%	997 $183,000
Q3 2018 Oct 26, 2018	SELL	$167.73 - $192.74 $13,586 - $15,611	-81 Reduced 6.21%	1,223 $235,000
Q1 2018 Apr 16, 2018	BUY	$151.6 - $177.13 $11,370 - $13,284	75 Added 6.1%	1,304 $213,000
Q4 2017 Jan 24, 2018	BUY	$137.28 - $155.55 $168,717 - $191,170	1,229	1,229 $184,000

Others Institutions Holding VRTX

# of Institutions

1,752

Shares Held

227M

Call Options Held

1.63M

Put Options Held

1.47M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baldwin Brothers LLC with notifications on news.

Account

Baldwin Brothers LLC Vertex Pharmaceuticals Inc Transaction History